LAURUSLABS Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,778 Cr
verified against source
Revenue YoY
26%
reported change
EBITDA
₹485 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laurus Labs delivered a strong Q3 FY2026 with INR 1,778 crore revenue (+26% YoY) and 27% EBITDA margin (90bps expansion YoY). The generic division drove results with 37% growth to INR 1,327 crore, anchored by ARV volume gains and new developed market launches. CDMO revenue of INR 408 crore was softer sequentially due to delivery phasing but management maintained confidence in full-year 50%+ growth trajectory. Gross margins of ~60% are expected to sustain going forward. Key investments are progressing—peptide qualification expected during CY2025, ADC GMP facility funded ($25 million), and KRKA Phase I on track for mid-2027. ROCE improved to 18.5% with target to reach 1.1x asset turn from current 0.91x. Risks include CDMO lumpiness impacting quarterly visibility, new modality (ADC/gene therapy) monetization not expected for 24+ months, and rising net debt (INR 2,092 crore) amid heavy CapEx (INR 1,000 crore annually).
Colored figures show movement against the previous available record.
Guidance to track
- Annual capital expenditure expected at INR 1,000 crore for FY2026, with similar levels anticipated for FY2027 as well, supporting capacity expansions across peptides, KRKA, and ADC facilities.
- Management expects to maintain gross margins of approximately 60% in the coming quarters and through the next financial year, supported by favorable product mix and process improvements.
- Revised ARV annual revenue guidance to INR 2,600 ± 200 crore, up from prior INR 2,500 ± 200 crore, driven by expanded API capacities meeting customer demand.
- Management targets improving asset turnover from current 0.91x toward 1.1x (five-year average) over time, with peak historical performance at 1.4x.
Risks flagged
- Sequential CDMO revenue declined 13% in Q3 despite full-year 50%+ growth guidance. Analysts questioned whether Q3 represents a sustainable quarterly base or lumpiness from once/twice-yearly supply patterns. Management deflected quarterly analysis, recommending annual view only.
- ADC GMP facility ($25 million allocated) and gene therapy process development labs will not generate meaningful revenues for at least 24 months, with all expenditures expensed through P&L rather than capitalized.
- Bio revenues will stagnate until the new fermentation facility at WSAC (400+ kiloliters Phase I) becomes operational toward end of 2026, with asset turnover currently constrained at 0.91x.
- Q3 cash conversion hit 113% of EBITDA partly due to customer advances, which management acknowledged as not fully sustainable. Analyst questioned longer-term sustainable conversion rate assumption of 80%+ versus historical 63%.
Key quotes
- We decided not to enter into large-scale mAb manufacturing. We don't want to do that. The other area we decided not to enter right now is also sterile manufacturing.
- CDMO margins are on the top, formulation on the higher side, and API on the lower side. The order remains same.
- We expect to sustain those [non-ARV formulations] because of additional capacities coming up for our CMO partner in Europe and also volume gain in the U.S. and also some new launches in North America.
Research modules